Profile data is unavailable for this security.
About the company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
- Revenue in EUR (TTM)38.50bn
- Net income in EUR6.17bn
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|SAN:PAR since |
|Amunix Pharmaceuticals Inc||Announced||21 Dec 2021||21 Dec 2021Announced||5.56%||1.25bn|
|American Finance Trust Inc-Office Building(3)||Deal completed||20 Dec 2021||20 Dec 2021Deal completed||5.57%||261.00m|
|ORIGIMM Biotechnology GmbH||Announced||01 Dec 2021||01 Dec 2021Announced||9.38%||--|
|Kadmon Holdings Inc||Deal completed||08 Sep 2021||08 Sep 2021Deal completed||5.50%||1.76bn|
|Translate Bio Inc||Deal completed||03 Aug 2021||03 Aug 2021Deal completed||5.74%||3.04bn|